SCHEMBL2295640

SCHEMBL2295640

Cc1ccc(S(=O)(=O)Oc2ccc(C(=O)CN[C@@H](C)c3ccccc3)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 3/20 0.49
ALDH1A1 P00352 6/20 0.47
LMNA P02545 2/20 0.47
ENPP1 P22413 3/20 0.47
ENPP3 O14638 2/20 0.47
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MAPT P10636 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PPARG P37231 1/20 0.45
HPGD P15428 2/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
ADAMTS4 O75173 1/20 0.43
EGFR P00533 1/20 0.43
RECQL P46063 1/20 0.42
HSD11B1 P28845 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2297311 1.00 ENPP2 (0.49) ENPP2ALDH1A1LMNAENPP1ENPP3
SCHEMBL2295636 1.00 ENPP2 (0.49) ENPP2ALDH1A1LMNAENPP1ENPP3
SCHEMBL2294630 0.93 ADAMTS4 (0.46) ENPP2ALDH1A1ENPP1ENPP3MEN1
SCHEMBL2296973 0.93 ADAMTS4 (0.46) ENPP2ALDH1A1ENPP1ENPP3MEN1
SCHEMBL2294632 0.93 ADAMTS4 (0.46) ENPP2ALDH1A1ENPP1ENPP3MEN1
SCHEMBL2294139 0.83 APAF1 (0.43) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL2296506 0.83 APAF1 (0.43) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL2294142 0.83 APAF1 (0.43) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL27711296 0.81 MEN1 (0.46) ENPP2ALDH1A1LMNAENPP1ENPP3
SCHEMBL27711233 0.81 MEN1 (0.46) ENPP2ALDH1A1LMNAENPP1ENPP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-06-18 US claimed
US-20110257392-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI-AVENTIS (FR) 2011-10-20 US disclosed
US-20110251385-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI-AVENTIS (FR) 2011-10-13 US disclosed
US-7994315-B2 Intermediate compound for synthesizing pharmaceutical agent and production method thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed
EP-2221305-A1 Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent Mitsubishi Tanabe Pharma Corporation (JP) 2010-08-25 EP disclosed
EP-2221304-A1 Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent Mitsubishi Tanabe Pharma Corporation (JP) 2010-08-25 EP disclosed
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257392-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 ENPP2 4554/4885ALDH1A1 1251/4885LMNA 3268/4885
US-20110251385-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 ENPP2 4554/4885ALDH1A1 1251/4885LMNA 3268/4885
US-20090156804-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 ENPP2 4554/4885ALDH1A1 1251/4885LMNA 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.